SCHEMBL186316

SCHEMBL186316

NC(=O)c1cc(C(N)=O)cc(-c2ccccc2)c1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 6/20 0.85
POLB P06746 1/20 0.58
CYP3A4 P08684 1/20 0.58
PARP1 P09874 1/20 0.58
MAPT P10636 1/20 0.58
TSHR P16473 1/20 0.58
CYP2C19 P33261 1/20 0.58
RECQL P46063 1/20 0.58
BLM P54132 1/20 0.58
PMP22 Q01453 1/20 0.58
HSD17B10 Q99714 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
MKNK1 Q9BUB5 3/20 0.56
MKNK2 Q9HBH9 2/20 0.56
KMO O15229 1/20 0.52
IKBKB O14920 2/20 0.50
PRSS1 P07477 1/20 0.50
PRSS2 P07478 1/20 0.50
PRSS3 P35030 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18120862 0.92 DHODH (1.00) DHODHPOLBCYP3A4PARP1MAPT
SCHEMBL30387022 0.92 DHODH (1.00) DHODHPOLBCYP3A4PARP1MAPT
SCHEMBL1516770 0.91 DHODH (0.71) DHODHPOLBCYP3A4PARP1MAPT
SCHEMBL3781228 0.88 DHODH (0.68) DHODHPOLBCYP3A4PARP1MAPT
SCHEMBL30116316 0.86 DHODH (0.66) DHODHPOLBCYP3A4PARP1MAPT
SCHEMBL17485202 0.86 DHODH (0.66) DHODHPOLBCYP3A4PARP1MAPT
SCHEMBL43553 0.84 DHODH (0.70) DHODHPOLBCYP3A4PARP1MAPT
SCHEMBL27446284 0.84 MKNK1 (0.76) DHODHPOLBCYP3A4PARP1MAPT
SCHEMBL29788172 0.84 DHODH (0.70) DHODHPOLBCYP3A4PARP1MAPT
Biphenyl SCHEMBL659450 0.83 MAPT (0.84) DHODHPOLBCYP3A4PARP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025068371-A1 INHIBITORS OF THE PROPROTEIN CONVERTASE FURIN, METHODS OF PRODUCTION THEREOF AND USE PHILIPPS-UNIVERSITÄT MARBURG (DE) 2025-04-03 WO disclosed
US-20220235087-A1 MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE FIMBRION THERAPEUTICS, INC. 2022-07-28 US disclosed
US-10559828-B2 Slurry for lithium ion secondary battery positive electrodes ZEON CORPORATION (JP) 2020-02-11 US disclosed
CN-108778288-A It can be used for treating antagonist derived from the mannose of the FimH of disease 菲姆布里昂医疗公司 2018-11-09 CN disclosed
EP-2953193-B1 SLURRY FOR LITHIUM ION SECONDARY BATTERY POSITIVE ELECTRODES ZEON CORP (JP) 2018-04-25 EP disclosed
US-9748547-B2 Method for producing electrode/separator laminate, and lithium-ion rechargeable battery ZEON CORPORATION (JP) 2017-08-29 US disclosed
US-20150357648-A1 SLURRY FOR LITHIUM ION SECONDARY BATTERY POSITIVE ELECTRODES ZEON CORPORATION (JP) 2015-12-10 US disclosed
EP-2953193-A1 SLURRY FOR LITHIUM ION SECONDARY BATTERY POSITIVE ELECTRODES Zeon Corporation (JP) 2015-12-09 EP disclosed
US-20150311490-A1 METHOD FOR PRODUCING ELECTRODE/SEPARATOR LAMINATE, AND LITHIUM-ION RECHARGEABLE BATTERY ZEON CORPORATION (JP) 2015-10-29 US disclosed
US-9159992-B2 Negative electrode active material for lithium ion secondary battery and lithium ion secondary battery ZEON CORPORATION (JP) 2015-10-13 US disclosed
EP-2924781-A1 METHOD FOR PRODUCING ELECTRODE/SEPARATOR LAMINATE, AND LITHIUM-ION RECHARGEABLE BATTERY Zeon Corporation (JP) 2015-09-30 EP disclosed
EP-2403040-A1 NEGATIVE ELECTRODE ACTIVE MATERIAL FOR LITHIUM ION SECONDARY BATTERY, AND LITHIUM ION SECONDARY BATTERY Zeon Corporation (JP) 2012-01-04 EP disclosed
US-3991015-A High molecular weight copolyamides containing quinazoline dione units BAYER AKTIENGESELLSCHAFT (DT) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235087-A1 MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE MAN2B2, MAN2A1, MANBA DHODH 767/4885POLB 3683/4885CYP3A4 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.